A MULTI-CENTRE, OPEN LABEL, SINGLE-ARM STUDY INTENDED TO FURTHER INVESTIGATE THE SAFETY AND EFFICACY OF PLERIXAFOR AS A FRONT-LINE MOBILISATION AGENT IN COMBINATION WITH G-CSF IN PATIENTS WITH LYMPHOMA OR MM (MULTIPLE MYELOMA).: